Alcohol is one of the most dangerous drugs, yet its presence is ubiquitous in social settings and celebrations 
Apple Pay Set for India Launch With Axis Bank 
AstraZeneca Q2 Earnings Beat Forecasts as Oncology Growth Supports 2026 Outlook 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
fnny Beta Launches With a Simple Idea: Find an Event, Show Up, Get Rewarded 
US Federal Register Drops Alibaba Qwen AI Search Tool 
Trump Administration Bars U.S. Travelers From Congo Flights Amid Ebola Outbreak 
3 clinical-grade skincare creams you really shouldn’t buy online 
Westinghouse Targets $50 Billion Valuation in U.S. IPO 
Prysmian, Rio Tinto Supply Low-Carbon Cables for Amazon Ohio Data Center 
France Keeps Top Health Alert as Officials Brace for Another Heatwave 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
SoftBank Launches $11 Billion Bond Sale to Fund OpenAI Investment 
CNN, MS NOW and Politico Sue Trump Over White House Media Ban 
Allegro Raises 2026 Outlook as International GMV Surges 
Volvo Cars Plans 13 New Models by 2030 to Boost Sales 
Add as a preferred source on Google
British pharmaceutical giant GSK plc (LON:GSK) is reportedly in advanced negotiations to acquire U.S.-based cancer drug developer Nuvalent Inc. (NASDAQ: NUVL) in a deal that could be worth more than $9 billion, according to a report published by the Financial Times on Tuesday.
Sources familiar with the matter said both companies are working toward finalizing an agreement as early as this week. However, discussions remain ongoing, and there is still a possibility that the deal could fall through if last-minute challenges arise.
If completed, the proposed acquisition would value Massachusetts-headquartered Nuvalent between $9 billion and $10 billion. The valuation represents a substantial premium over Nuvalent’s market capitalization, which stood at nearly $7 billion at the close of trading on Monday.
The potential takeover would mark GSK’s largest acquisition in more than a decade and rank among the most significant transactions in the company’s history. The move aligns with CEO Luke Miels’ strategy to expand and strengthen GSK’s oncology portfolio as the pharmaceutical industry increasingly focuses on innovative cancer treatments.
Nuvalent has gained attention for its work in developing targeted cancer therapies designed to address resistance mechanisms in tumors. Its lead drug candidate, neladalkib, is being developed for the treatment of lung cancer and is currently under review by U.S. regulators. Approval of the therapy could significantly enhance Nuvalent’s value and commercial prospects.
The reported deal comes during a period of heightened activity in the global biotechnology sector. According to Dealogic data cited in the report, biotech and pharmaceutical mergers and acquisitions have reached nearly $211 billion in announced transactions so far this year, highlighting strong demand for promising drug-development companies.
Should the acquisition move forward, it would further reinforce GSK’s commitment to cancer research and provide the company with valuable assets in the rapidly growing oncology market.
